Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
The net-zero target approval complements the company's near-term emission reduction targets
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Subscribe To Our Newsletter & Stay Updated
